<DOC>
	<DOC>NCT01935908</DOC>
	<brief_summary>The purpose of this study is to determine the feasibility of prospectively enrolling and randomizing patients with aneurysmal subarachnoid hemorrhage (aSAH) to receive levetiracetam or not to receive levetiracetam, and documenting in-hospital and follow-up clinical variables.</brief_summary>
	<brief_title>Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>≥ 18 years of age ≤ 75 years of age Newly diagnosed aneurysmal subarachnoid hemorrhage One or more antiepileptic medication is taken as a preadmission medication Seizure occurrence in the field or in the emergency department, or anytime before consent could be obtained Inability to obtain informed consent from the patient, or from the patient's appropriate surrogate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Subarachnoid Hemorrhage</keyword>
	<keyword>Seizures</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Levetiracetam</keyword>
</DOC>